Department of Medicine, Department of Biochemistry, Louisiana Health Science Center-Shreveport, Shreveport, LA 71103, USA.
Int J Mol Sci. 2023 Aug 29;24(17):13369. doi: 10.3390/ijms241713369.
DNA damage repair lies at the core of all cells' survival strategy, including the survival strategy of cancerous cells. Therefore, targeting such repair mechanisms forms the major goal of cancer therapeutics. The mechanism of DNA repair has been tousled with the discovery of multiple kinases. Recent studies on tousled-like kinases have brought significant clarity on the effectors of these kinases which stand to regulate DSB repair. In addition to their well-established role in DDR and cell cycle checkpoint mediation after DNA damage or inhibitors of replication, evidence of their suspected involvement in the actual DSB repair process has more recently been strengthened by the important finding that TLK1 phosphorylates RAD54 and regulates some of its activities in HRR and localization in the cell. Earlier findings of its regulation of RAD9 during checkpoint deactivation, as well as defined steps during NHEJ end processing, were earlier hints of its broadly important involvement in DSB repair. All this has opened up new avenues to target cancer cells in combination therapy with genotoxins and TLK inhibitors.
DNA 损伤修复是所有细胞生存策略的核心,包括癌细胞的生存策略。因此,针对这些修复机制成为癌症治疗的主要目标。随着多种激酶的发现,DNA 修复机制变得复杂。最近对绒毛状激酶的研究为这些激酶的效应物带来了显著的清晰度,这些效应物有望调节 DSB 修复。除了它们在 DDR 中的既定作用以及在 DNA 损伤或复制抑制剂后细胞周期检查点的介导作用外,最近的重要发现表明,TLK1 磷酸化 RAD54 并调节 HRR 中的一些活性及其在细胞中的定位,这进一步证实了它们在实际 DSB 修复过程中的可疑参与。其在检查点失活期间对 RAD9 的调节的早期发现,以及在 NHEJ 末端处理过程中的明确步骤,是其在 DSB 修复中广泛参与的早期暗示。所有这些都为与遗传毒素和 TLK 抑制剂联合治疗癌症细胞开辟了新途径。